The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels

J Infect Dis. 2006 Jan 15;193(2):251-8. doi: 10.1086/498909. Epub 2005 Dec 13.

Abstract

Background: This study was designed to examine the relationship between the timing of antibiotic treatment and both survival rates and hemodynamic/inflammatory correlates of survival in a murine model of Escherichia coli septic shock.

Methods: Surgical implantation of an E. coli (O18:K1:H7)-laced, gelatin capsule-encased fibrinogen clot was used to generate a bacteremic model of murine septic shock. Survival duration, hemodynamic responses, and circulating serum tumor necrosis factor (TNF)-alpha , interleukin (IL)-6, and lactate levels were assessed in relation to increasing delays in or absence of antibiotic treatment.

Results: A critical inflection point with respect to survival occurred between 12 and 15 h after implantation. When initiated at or before 12 h, antibiotic treatment resulted in < or = 20% mortality, but, when initiated at or after 15 h, it resulted in >85% mortality. Physiologically relevant hypotension developed in untreated septic mice by 12 h after implantation. Values for heart rate differed between untreated septic mice and sham-infected control mice by 6 h after implantation, whereas values for cardiac output and stroke volume did not differ until at least 18-24 h after implantation. Antibiotic treatment initiated > or = 12 h after implantation was associated with persistence of increased circulating serum lactate, TNF- alpha , and IL-6 levels.

Conclusions: The timing of antibiotic treatment relative to hypotension is closely associated with survival in this murine model of septic shock. Delay in antibiotic treatment results in the persistence of inflammatory/stress markers even after antibiotic treatment is initiated.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Cardiac Output
  • Disease Models, Animal
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / mortality
  • Escherichia coli Infections / physiopathology
  • Heart Rate
  • Hypotension / physiopathology*
  • Interleukin-6 / blood
  • Lactic Acid / blood
  • Male
  • Mice
  • Shock, Septic / drug therapy*
  • Shock, Septic / microbiology
  • Shock, Septic / mortality
  • Shock, Septic / physiopathology
  • Statistics as Topic
  • Stroke Volume
  • Survival Analysis
  • Time Factors
  • Tumor Necrosis Factor-alpha / analysis

Substances

  • Anti-Bacterial Agents
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Lactic Acid